List of Excipients in Branded Drug PAXILCR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	PAXILCR	paroxetine hydrochloride	54868-5347	GLYCERYL BEHENATE
Physicians Total Care Inc	PAXILCR	paroxetine hydrochloride	54868-5347	HYPROMELLOSES
Physicians Total Care Inc	PAXILCR	paroxetine hydrochloride	54868-5347	LACTOSE MONOHYDRATE
Physicians Total Care Inc	PAXILCR	paroxetine hydrochloride	54868-5347	MAGNESIUM STEARATE

Paxil CR Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Paxil CR is the controlled-release formulation of paroxetine, a selective serotonin reuptake inhibitor marketed in 12.5 mg, 25 mg, and 37.5 mg strengths. Its commercial value is no longer based primarily on originator patent exclusivity. The strongest opportunities are generic controlled-release development, excipient and release-profile optimization, manufacturing-cost reduction, and differentiated oral products for patients who need once-daily paroxetine exposure.

The product uses a controlled-release tablet architecture rather than a conventional immediate-release paroxetine tablet. The formulation strategy must control drug release, preserve dose uniformity across strengths, limit dose dumping, and maintain bioequivalence against the reference listed drug. The principal development barrier is formulation performance, not biosimilar complexity or biologic manufacturing.

What is Paxil CR and how does its formulation work?

Paxil CR contains paroxetine as the active pharmaceutical ingredient and is administered once daily. The product is designed to release paroxetine over an extended period, producing a slower absorption profile than immediate-release paroxetine tablets.[1]

Attribute	Paxil CR
Active ingredient	Paroxetine
Drug class	Selective serotonin reuptake inhibitor
Dosage form	Controlled-release oral tablet
Strengths	12.5 mg, 25 mg, 37.5 mg
Administration	Once daily
Regulatory pathway	New drug application, followed by generic ANDA pathway
Biologic status	Small molecule; biosimilar pathway does not apply
Primary formulation challenge	Reproducing the reference product’s extended-release profile
Primary commercial opportunity	Generic or differentiated controlled-release paroxetine

Paxil CR should not be treated as a simple strength-for-strength substitute for immediate-release paroxetine. The release rate affects pharmacokinetics, peak exposure, tolerability, and the feasibility of a biowaiver or abbreviated approval strategy.

What excipients are used in Paxil CR?

Public labeling identifies excipient classes used in Paxil CR, including hypromellose, povidone, lactose, magnesium stearate, colloidal silicon dioxide, and coating-related materials.[1] The precise commercial formulation should be confirmed against the current FDA labeling record and the reference-product pharmaceutical equivalence data before development decisions are made.

Excipient or excipient class	Likely formulation function	Commercial relevance
Hypromellose	Hydrophilic matrix and release control	Core variable for release kinetics and robustness
Povidone	Binder and granulation aid	Supports tablet strength and content uniformity
Lactose	Diluent and bulk-forming excipient	Affects compressibility, density, and potential intolerance positioning
Magnesium stearate	Lubricant	Excess levels can slow wetting and alter dissolution
Colloidal silicon dioxide	Glidant and flow aid	Supports manufacturing consistency
Film-coating polymers	Protection, identification, swallowability, and appearance	Can affect moisture protection and handling
Titanium dioxide, talc, polyethylene glycol, and colorants	Coating opacity, lubrication, flexibility, and color	Important for visual identification and process comparability

The formulation target is not simply a list of inactive ingredients. For a controlled-release product, excipient grade, particle size, substitution type, viscosity, moisture content, compression force, and coating weight can change dissolution behavior. A generic product may use different excipients if it demonstrates pharmaceutical equivalence and bioequivalence.

How does hypromellose affect Paxil CR release?

Hypromellose is the most commercially important excipient in a matrix-style controlled-release strategy. Upon hydration, it forms a gel layer that controls water penetration and drug diffusion. Higher-viscosity grades generally produce slower release, although polymer concentration, tablet porosity, drug loading, compression pressure, and lubricant level also matter.

A formulation team would typically screen:

• Hypromellose viscosity grade
• Polymer concentration
• Lactose-to-polymer ratio
• Tablet hardness and porosity
• Lubrication time and magnesium stearate level
• Coating composition and weight gain
• Dissolution performance across pH conditions
• Stability under high humidity and accelerated temperature

The optimal commercial formulation must match the reference dissolution profile without creating an unnecessarily expensive or difficult manufacturing process.

What formulation patents protect Paxil CR?

The original Paxil CR formulation was protected through a combination of product, formulation, and regulatory exclusivity rights. Those rights have largely aged out as commercial barriers to generic entry. A new applicant should not assume that the historical formulation patents provide a current blocking position.

The relevant intellectual-property categories are:

IP category	Relevance to Paxil CR
Active-ingredient patents	Generally limited because paroxetine is an established compound
Controlled-release formulation patents	Historically important; likely expired or commercially weak for current entry
Manufacturing patents	May cover granulation, matrix formation, coating, or process controls
Method-of-use patents	Could relate to depression, panic disorder, social anxiety disorder, or premenstrual dysphoric disorder
Trade secrets	May remain relevant for process parameters and scale-up knowledge
Trademark rights	Protect the Paxil and Paxil CR brands, not the generic formulation

A commercial review should distinguish between patents listed in the Orange Book and patents that remain enforceable and commercially relevant. Expired patents do not prevent ANDA approval. Method-of-use patents can create Paragraph IV litigation exposure if listed and implicated by the proposed label, but they do not necessarily prevent a carve-out strategy.

When does Paxil CR lose exclusivity?

Paxil CR has already passed the period in which originator exclusivity could support a protected branded market. Paroxetine immediate-release products and extended-release products have been available through generic channels for years. The practical market question is therefore not when Paxil CR loses exclusivity, but whether a new controlled-release product can obtain approval and compete on price, supply reliability, or formulation differentiation.

Exclusivity or protection	Commercial status
New chemical entity exclusivity	Expired
Historical formulation protection	No longer a dependable entry barrier
Brand trademark	Continues to protect the Paxil CR name
Orange Book patent barrier	Must be checked against the current FDA listing
Generic competition	Established or commercially feasible
Biosimilar exclusivity	Not applicable

The FDA Orange Book remains the controlling source for current listed patents, patent-use codes, and regulatory exclusivity.[2]

What is the Orange Book status of Paxil CR?

Paxil CR is a small-molecule prescription product regulated through an NDA. Generic versions would generally use the ANDA pathway and demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

The commercial diligence points are:

1. Confirm the current reference listed drug and NDA record.
2. Review active Orange Book patents and use codes.
3. Identify any remaining pediatric or other regulatory exclusivity.
4. Review approved strengths and dosage-form descriptions.
5. Confirm whether the reference product remains commercially available in every proposed strength.
6. Compare the proposed formulation with the reference product’s dissolution and pharmacokinetic profile.

The existence of an NDA does not mean that the brand retains meaningful market exclusivity. Orange Book status must be reviewed by product strength and current edition.

Which companies are challenging Paxil CR exclusivity?

Paxil CR is not a biologic, so biosimilar companies are not the relevant competitive group. The relevant challengers are generic pharmaceutical manufacturers with controlled-release oral solid-dose capabilities.

Potential competitor categories include:

• Large generic manufacturers with established ANDA operations
• Contract development and manufacturing organizations
• Specialty generic companies focused on modified-release products
• Regional manufacturers seeking low-cost antidepressant portfolios
• Companies pursuing authorized-generic or license-based supply arrangements

A Paragraph IV challenger would need to address the listed patent claims and demonstrate that its product is not infringing, that the claims are invalid, or that the relevant patents are unenforceable. Once the remaining patent barriers are absent or expired, a standard ANDA strategy becomes more attractive than a litigation-led launch.

What generic entry risks exist for Paxil CR?

The primary risks are technical and commercial.

Technical risks

• Failure to match the reference product’s absorption profile
• Dissolution divergence at critical time points
• Dose dumping under alcohol or altered gastrointestinal conditions
• Inadequate content uniformity at the 12.5 mg strength
• Scale-up changes in granulation, compression, or coating
• Excipient variability between suppliers
• Stability failure caused by moisture uptake
• Food-effect differences
• Failure to demonstrate bioequivalence in a sensitive study design

Commercial risks

• Low reimbursement pricing
• Limited market size relative to high-volume immediate-release antidepressants
• Existing generic competition
• Substitution toward newer antidepressants
• Brand erosion and reduced physician familiarity
• Supply-chain pressure on low-margin oral solids
• Potential discontinuation of the reference product or selected strengths

The 12.5 mg strength may have particular value for dose initiation and titration, but it can be more difficult to manufacture economically because the active load is low and content-uniformity requirements are demanding.

How can excipient strategy create commercial differentiation?

A generic company can pursue several excipient strategies without relying on a new active ingredient.

Low-cost reference-like formulation

This approach uses widely available excipients and a conventional controlled-release matrix. Its advantage is lower development and manufacturing cost. Its weakness is limited differentiation and direct price competition.

Robustness-focused formulation

The developer can select excipient grades that reduce sensitivity to compression force, humidity, and lot-to-lot variability. This may lower batch failure rates and improve supply reliability. The value is operational rather than visible to prescribers.

Lactose-reduced or lactose-free formulation

If the reference formulation contains lactose, a lactose-reduced alternative could support positioning for patients or markets where lactose avoidance is commercially relevant. The change must not impair release behavior, tablet strength, or bioequivalence.

Lower-pill-burden packaging

Once-daily dosing is already a product advantage. A manufacturer can reinforce this benefit through calendar packaging, adherence packaging, and supply configurations aimed at chronic-use patients.

Improved swallowability

Film-coating optimization, tablet dimensions, surface finish, and reduced tablet friability can support patient acceptance. These changes may be commercially useful even when the active ingredient and release profile remain unchanged.

Alternative manufacturing platform

A multiparticulate, coated-pellet, or capsule-based product could offer technical differentiation, but it would likely require a more complex regulatory and bioequivalence strategy. The commercial return would need to justify the added development cost.

What manufacturing and IP barriers affect Paxil CR?

The main manufacturing barrier is consistent control of the extended-release profile at commercial scale. Laboratory dissolution results do not guarantee scale-up performance. Critical process parameters may include:

• Granulation endpoint
• Binder addition rate
• Drying temperature and residual moisture
• Milling conditions
• Lubrication time
• Compression force
• Tablet porosity
• Coating weight gain
• In-process dissolution controls

Process patents may be less important than manufacturing know-how. A company that can produce a stable, reproducible product with low reject rates may compete effectively even without a legally differentiated formulation.

The strongest defensible IP opportunity is likely to arise from a genuinely differentiated delivery system, manufacturing process, or patient-use feature rather than a routine substitution of one pharmacopeial excipient for another. New patent claims must satisfy novelty and non-obviousness requirements and should be supported by comparative performance data.

What licensing deals could support Paxil CR commercialization?

Licensing opportunities fall into four categories:

Deal type	Potential value
ANDA or dossier licensing	Accelerates market entry where a partner already has approval or development data
Contract manufacturing	Reduces capital requirements and supports regional launches
Authorized-generic arrangement	Provides controlled access to brand-linked supply and regulatory know-how
Excipient or delivery-technology license	Supports differentiated release performance or manufacturing efficiency

A license is most attractive when it provides regulatory data, reference-product characterization, an established manufacturing site, or market access. A simple license to a routine excipient combination is unlikely to create durable value.

How does Paxil CR compare with immediate-release paroxetine?

Factor	Paxil CR	Immediate-release paroxetine
Dosing profile	Controlled release, generally once daily	Immediate release, generally once daily
Formulation complexity	Higher	Lower
Bioequivalence burden	Higher because release profile matters	More conventional
Manufacturing cost	Higher	Lower
Generic competition	More technically selective	Broad and mature
Differentiation potential	Release control, tolerability, adherence	Price and supply
Excipient sensitivity	High	Moderate
Commercial opportunity	Specialty generic or differentiated ER product	Commodity generic

Paxil CR offers a narrower but potentially more defensible generic opportunity than immediate-release paroxetine. The product is attractive to manufacturers with modified-release expertise, but less attractive to companies seeking the lowest-cost entry into the antidepressant market.

What revenue exposure and commercial opportunity exist?

Current brand revenue for Paxil CR is not reliably disclosed as a standalone product in public financial reporting. The originator opportunity is therefore limited unless the product is relaunched, repositioned, or supported through a licensing or authorized-generic arrangement.

The principal commercial opportunities are:

1. A controlled-release ANDA with competitive pricing.
2. Regional supply in markets with limited modified-release competition.
3. A differentiated formulation with improved stability or tolerability.
4. Contract manufacturing for an existing marketing authorization holder.
5. A portfolio strategy combining immediate-release and extended-release paroxetine.
6. Lifecycle management through adherence packaging or selected dosage strengths.

The economic case depends on forecast volume, reimbursement, API cost, manufacturing yield, regulatory expense, and the number of approved competitors. A single-product launch has higher exposure to price erosion than a broader antidepressant portfolio.

What patent litigation and settlement risk applies?

A new entrant should screen for:

• Current Orange Book patent listings
• Any pending Paragraph IV notice
• ANDA litigation under the Hatch-Waxman framework
• Licensing or supply settlements
• Authorized-generic arrangements
• State or federal competition concerns tied to settlement terms

Because Paxil CR is a mature small-molecule product, litigation risk is likely to be lower than for a newly launched modified-release drug with active formulation patents. The key legal risk is not biosimilar litigation. It is whether any remaining listed formulation or method-of-use patent can delay approval or constrain the proposed label.

Key Takeaways

• Paxil CR is a controlled-release paroxetine tablet available in 12.5 mg, 25 mg, and 37.5 mg strengths.
• Hypromellose is the central release-controlling excipient in a matrix-based development strategy.
• Povidone, lactose, magnesium stearate, colloidal silicon dioxide, and coating materials affect manufacturability and dissolution performance.
• The product is a small molecule; biosimilar regulation does not apply.
• Historical originator exclusivity is no longer the primary commercial barrier.
• Generic development risk centers on bioequivalence, dissolution matching, dose-dumping control, and scale-up.
• The strongest opportunity is a cost-efficient, robust controlled-release ANDA or a differentiated formulation with a credible manufacturing advantage.
• Patent value is likely to be greater in new delivery or manufacturing technology than in routine excipient substitutions.
• Commercial returns are constrained by mature antidepressant competition and likely price erosion.
• A current FDA Orange Book review is required before relying on any patent or exclusivity conclusion.

FAQs

Is Paxil CR the same as generic paroxetine?

No. Generic immediate-release paroxetine is not automatically substitutable for a controlled-release paroxetine product. The dosage form and release profile must be evaluated separately.

Can a manufacturer change the excipients in a Paxil CR generic?

Yes. An ANDA applicant may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling.

Is hypromellose required in every Paxil CR generic?

No. Hypromellose is a common controlled-release polymer, but another release-controlling system may be used if it produces an equivalent product profile and satisfies regulatory requirements.

Does Paxil CR have biosimilar competition?

No. Paxil CR contains paroxetine, a small-molecule active ingredient. Competitive products would generally be approved as generics, not biosimilars.

What is the most attractive excipient opportunity for Paxil CR?

The strongest opportunity is an excipient system that improves release robustness, moisture stability, manufacturability, or patient acceptability without materially increasing cost or creating a difficult bioequivalence program.

References

1. U.S. Food and Drug Administration. (n.d.). Paxil CR (paroxetine) controlled-release tablets: Prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2015). ANDAs for certain highly variable drugs: Guidance for industry.
4. U.S. Food and Drug Administration. (2022). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).